参仙升脉口服液治疗缓慢性心律失常疗效与安全性的meta分析

发布时间：2018-06-22 17:19

本文选题：参仙升脉口服液 + 缓慢性心律失常　；参考：《辽宁中医药大学》2016年硕士论文

【摘要】：目的:系统评价治疗缓慢性心律失常的临床有效性和安全性,为临床治疗提供循证依据。方法:计算机检索CNKI相关期刊论文、万方数据库、重庆维普数据库、中国生物医学文献数据库等收集自2011-2016年参仙升脉口服液(治疗组)相比其他药物(对照组)治疗缓慢性心律失常的RCT试验,实验由两名专业人员依据纳入和排除标准独立评价文献质量,提取资料后交叉核对,采用Rev Man 5.33统计软件进行Meta分析。评价指标:临床疗效、平均心率、不良反应等。结果:共纳入16项RCT,合计1078例患者。与对照组比较,(1)15篇文献比较了参仙升脉口服液与对照组的临床疗效:各研究间无统计学异质性(P=0.98,I2=0%),应用固定效应模型进行分析。结果显示:[OR合并=4.55,95%CI(3.10,6.68),P0.00001],提示参仙升脉口服液组临床疗效优于对照组。(2)14篇文献比较了参仙升脉口服液与对照组平均心率的提高情况,各研究间有统计学异质性(P0.00001,I2=93%),采用随机效应模型分析,结果显示:[MD=5.81,95%CI(3.72,7.90),P0.00001],提示参仙升脉口服液组平均心率的提高幅度优于对照组;(3)9篇文献比较了参仙升脉口服液与对照组的不良事件发生率情况,各研究间有统计学异质性(P=0.0005,I2=71%),采用随机效应模型分析。结果提示:[OR=0.20,95%CI(0.06,0.67),P=0.09),参仙升脉组不良反应事件发生率小于对照组。结论:目前的数据表明参仙升脉口服液的临床疗效、平均心率的提高均优于其他药物,服用参仙升脉口服液组不良反应小于对照组。但限于纳入研究文献的局限性,尚需更多高质量的随机对照试验予以证实。
[Abstract]:Objective: to evaluate the clinical efficacy and safety of the treatment of bradyarrhythmia and provide evidence-based basis for clinical treatment. Methods: CNKI Chinese periodical full-text database, Wanfang database, Chongqing Weipu database were searched by computer. The RCT test of Shenxianshengmai oral liquid (treatment group) in treating bradyarrhythmia compared with other drugs (control group) was collected from the Chinese Biomedical Literature Database from 2011 to 2016. The quality of literature was evaluated by two professionals according to the inclusion and exclusion criteria. The data were extracted and cross-checked, and Meta-analysis was carried out with Rev Man 5.33 statistical software. Evaluation measures: clinical efficacy, mean heart rate, adverse reactions and so on. Results: a total of 16 RCTs were included in 1078 patients. Compared with the control group, (1) the clinical efficacy of Shenxian Shengmai Oral liquid was compared with that of the control group. There was no statistical heterogeneity between the two groups (P < 0. 98%), and the fixed effect model was used to analyze it. The results showed that: [OR combined with 4.55.95 CI (3.106.68) P 0.00001] suggested that the clinical efficacy of Shenxian Shengmai oral liquid group was better than that of control group. (2) the increase of mean heart rate of Shenxian Shengmai oral liquid was compared with that of control group in 14 articles. There was statistical heterogeneity among the studies (P 0.00001). The random effect model was used to analyze the heterogeneity between the two studies. The results showed that the mean heart rate in Shenxian Shengmai oral liquid group was better than that in control group, and the incidence of adverse events in Shenxian Shengmai oral liquid was compared with that in control group. There was statistical heterogeneity among the studies (P < 0.0005 / I _ 2H _ (71%), and the random effect model was used to analyze it. The results suggested that the incidence of adverse events in the Shenxian Shengmai group was lower than that in the control group. Conclusion: the current data show that Shenxian Shengmai oral liquid has better clinical efficacy and average heart rate than other drugs, and the adverse reaction of Shenxian Shengmai oral liquid group is smaller than that of control group. However, limited to the limitations of the research literature, more high-quality randomized controlled trials are needed to confirm it.
【学位授予单位】：辽宁中医药大学
【学位级别】：硕士
【学位授予年份】：2016
【分类号】：R259

【相似文献】